Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders

References

• Dressler W, Stein R. [About Justus Liebig‘s hydroxylurea]. Ann. Chem. Pharm.150, 242–252 (1869).
   Google Scholar
• Rosenthal F, Wislicki L. [About the relationship between the most lethal blood poisons and degradation products of proteins: a contribution to the etiology of pernicious anemia]. Kollek. Klin. Wochenschr.7, 972–977 (1928).
   Google Scholar
• Stearns B, Losee KA, Bernstein J. Hydroxyurea a new type of potential antitumor agent. J. Med. Chem.6, 201 (1963).
   PubMed Web of Science ®Google Scholar
• Stock CC, Clarke DA, Philips FS et al. Sarcoma 180 screening data. Cancer Res.20(5 Pt 2), 193–381 (1960).
   PubMed Web of Science ®Google Scholar
• Donehower RC. An overview of the clinical experience with hydroxyurea. Semin. Oncol.19(3 Suppl. 9), 11–19 (1992).
   PubMed Web of Science ®Google Scholar
• Stevens MR. Hydroxyurea: an overview. J. Biol. Regul. Homeost. Agents13(3), 172–175 (1999).
   PubMedGoogle Scholar
• Rodriguez GI, Kuhn JG, Weiss GR et al. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood91(5), 1533–1541 (1998).
   PubMed Web of Science ®Google Scholar
• Gwilt PR, Tracewell WG. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin. Pharmacokinet.34(5), 347–358 (1998).
   PubMed Web of Science ®Google Scholar
• Yan JH, Ataga K, Kaul S et al. The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. J. Clin. Pharmacol.45(4), 434–445 (2005).
   PubMed Web of Science ®Google Scholar
• Krakoff IH, Brown NC, Reichard P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res.28(8), 1559–1565 (1968).
   PubMed Web of Science ®Google Scholar
• Moore EC, Hurlbert RB. The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY). Pharmacol. Ther.27(2), 167–196 (1985).
   PubMed Web of Science ®Google Scholar
• Szekeres T, Fritzer-Szekeres M, Elford HL. The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy. Crit. Rev. Clin. Lab. Sci.34(6), 503–528 (1997).
   PubMed Web of Science ®Google Scholar
• Yarbro JW. Mechanism of action of hydroxyurea. Semin. Oncol.19(3 Suppl. 9), 1–10 (1992).
   PubMed Web of Science ®Google Scholar
• Schrell UM, Rittig MG, Anders M et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J. Neurosurg.86(5), 845–852 (1997).
   PubMed Web of Science ®Google Scholar
• Kramer OH, Knauer SK, Zimmermann D et al. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene27(6), 732–740 (2008).
   PubMedGoogle Scholar
• Lori F, Malykh A, Cara A et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science266(5186), 801–805 (1994).
   PubMed Web of Science ®Google Scholar
• Van den Berg C, Von Hoff DD. Use of hydroxyurea to alter drug resistance of human tumor cells. Cancer Treat. Res.78, 95–114 (1995).
   PubMedGoogle Scholar
• Harrison CN, Campbell PJ, Buck G et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med.353(1), 33–45 (2005).
   PubMed Web of Science ®Google Scholar
• Cokic VP, Smith RD, Beleslin-Cokic BB et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J. Clin. Invest.111(2), 231–239 (2003).
   PubMed Web of Science ®Google Scholar
• Hehlmann R. Current CML therapy: progress and dilemma. Leukemia17(6), 1010–1012 (2003).
   PubMedGoogle Scholar
• Frame D. Chronic myeloid leukemia: standard treatment options. Am. J. Health Syst. Pharm.63(23 Suppl. 8), S10–S14, quiz S21–S22 (2006).
   Google Scholar
• Silver RT. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia. Leukemia19(1), 39–43 (2005).
   PubMed Web of Science ®Google Scholar
• Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol.114(1), 26–40 (2005).
   PubMed Web of Science ®Google Scholar
• Berk PD, Goldberg JD, Silverstein MN et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N. Engl. J. Med.304(8), 441–447 (1981).
   PubMed Web of Science ®Google Scholar
• Fruchtman SM, Mack K, Kaplan ME et al. From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin. Hematol.34(1), 17–23 (1997).
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Finazzi G, Ruggeri M et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl. J. Med.332(17), 1132–1136 (1995).
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Scott LM, Buck G et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet366(9501), 1945–1953 (2005).
   PubMed Web of Science ®Google Scholar
• Kessler CM, Klein HG, Havlik RJ. Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br. J. Haematol.50(1), 157–167 (1982).
   PubMed Web of Science ®Google Scholar
• Palandri F, Catani L, Testoni N et al. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am. J. Hematol.84(4), 215–220 (2009).
   PubMed Web of Science ®Google Scholar
• Budde U, Scharf RE, Franke P et al. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood82(6), 1749–1757 (1993).
   PubMed Web of Science ®Google Scholar
• Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood90(9), 3370–3377 (1997).
   PubMed Web of Science ®Google Scholar
• Emadi A, Spivak JL. Anagrelide: 20 years later. Expert Rev. Anticancer Ther.9(1), 37–50 (2009).
   PubMed Web of Science ®Google Scholar
• Barbui T, Carobbio A, Rambaldi A et al. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood114(4), 759–763 (2009).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Gangat N, Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood109(9), 4105 (2007).
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Cassinat B, Chevret S et al. Pegylated interferon-α-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood112(8), 3065–3072 (2008).
   PubMed Web of Science ®Google Scholar
• Larsen TS, Bjerrum OW, Pallisgaard N et al. Sustained major molecular response on interferon α-2b in two patients with polycythemia vera. Ann. Hematol.87(10), 847–850 (2008).
   PubMed Web of Science ®Google Scholar
• Girodon F, Schaeffer C, Cleyrat C et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica93(11), 1723–1727 (2008).
   PubMedGoogle Scholar
• Ricksten A, Palmqvist L, Johansson P et al. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica93(8), 1260–1261 (2008).
   PubMed Web of Science ®Google Scholar
• Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood108, 3913–3915 (2006).
   PubMed Web of Science ®Google Scholar
• Larsen TS, Pallisgaard N, de Stricker K et al. Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. Hematology14(1), 11–15 (2009).
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Tosetto A, Frezzato M et al. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann. Intern. Med.139(6), 470–475 (2003).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Gangat N, Wolanskyj AP. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood108(7), 2493–2494 (2006).
   PubMedGoogle Scholar
• Randi ML, Ruzzon E, Tezza F et al. Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Platelets16(3–4), 181–184 (2005).
   PubMed Web of Science ®Google Scholar
• Lofvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur. J. Haematol.41(4), 375–381 (1988).
   PubMed Web of Science ®Google Scholar
• Barosi G, Besses C, Birgegard G et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia21(2), 277–280 (2007).
   PubMed Web of Science ®Google Scholar
• Lannemyr O, Kutti J. Hydroxyurea as a cause of drug fever in essential thrombocythaemia. Eur. J. Haematol.62(5), 354–355 (1999).
   PubMedGoogle Scholar
• Hallam MJ, Kolesar JM. Hydroxyurea induced acute elevations in liver function tests. J. Oncol. Pharm. Pract.14(1), 61–63 (2008).
   PubMedGoogle Scholar
• Gilbert HS. Modern treatment strategies in polycythemia vera. Semin. Hematol.40(1 Suppl. 1), 26–29 (2003).
   PubMed Web of Science ®Google Scholar
• Kojima K, Fujii N, Omoto E et al. Cyclic thrombocytopenia and polycythemia vera. Ann. Hematol.82(1), 61–63 (2003).
   PubMed Web of Science ®Google Scholar
• Tefferi A, Elliott MA, Kao PC et al. Hydroxyurea-induced marked oscillations of platelet counts in patients with polycythemia vera. Blood96(4), 1582–1584 (2000).
   PubMed Web of Science ®Google Scholar
• Burthem J, Chaudhry MS. Hydroxycarbamide associated platelet count oscillations in a patient with polycythaemia vera. A case report and review of the literature. Platelets19(3), 234–235 (2008).
   PubMed Web of Science ®Google Scholar
• Tauscher J, Siegel F, Petrides P. Hydroxyurea induced oscillations in twelve patients with polycythemia vera. Haematologica95(7), 1227–1229 (2010).
   PubMed Web of Science ®Google Scholar
• DumontWallon G, Milpied-Homsi B, Morineau N et al. Effets secondaires cutanéomuqueux de l’hydroxyurée: étude prospective sur 27 patients. Hematologie12(4), 262–266 (2006).
   Google Scholar
• Zaccaria E, Cozzani E, Parodi A. Secondary cutaneous effects of hydroxyurea: possible pathogenetic mechanisms. J. Dermatol. Treat.17(3), 176–178 (2006).
   PubMed Web of Science ®Google Scholar
• Jeevankumar B, Thappa DM. Blue lunula due to hydroxyurea. J. Dermatol.30(8), 628–630 (2003).
   PubMedGoogle Scholar
• Young HS, Khan AS, Kendra JR et al. The cutaneous side-effects of hydroxyurea. Clin. Lab. Haematol.22(4), 229–232 (2000).
   PubMedGoogle Scholar
• Best PJ, Petitt RM. Multiple skin cancers associated with hydroxyurea therapy. Mayo Clin. Proc.73(10), 961–963 (1998).
   PubMed Web of Science ®Google Scholar
• Jain V, Gupta K, Nagpal N. Perimalleolar ulcers in hydroxyurea treated patients with concomitant chronic venous disease: diagnostic pitfalls. J. Coll. Physicians Surg. Pak.15(10), 658–660 (2005).
   PubMedGoogle Scholar
• Kalambokis G, Stefanou D, Arkoumani E et al. Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-a and oral cytarabine ocfosfate for chronic myelogenous leukemia. Eur. J. Haematol.73(1), 67–70 (2004).
   PubMedGoogle Scholar
• Wong CC, Brown D, Howling SJ et al. Hydroxyurea-induced pneumonitis in a patient with chronic idiopathic myelofibrosis after prolonged drug exposure. Eur. J. Haematol.71(5), 388–390 (2003).
   PubMedGoogle Scholar
• Martinez A, Hinz JM, Gómez L et al. Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment. Mutat. Res.656(1–2), 1–7 (2008).
   PubMedGoogle Scholar
• Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat. Rev. Cancer8, 24–36 (2008).
   PubMed Web of Science ®Google Scholar
• Collins AR, Squires S, Johnson RT. Inhibitors of repair DNA synthesis. Nucleic Acids Res.10(4), 1203–1213 (1982).
   PubMed Web of Science ®Google Scholar
• Finazzi G, Ruggeri M, Rodeghiero F et al. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br. J. Haematol.110(3), 577–583 (2000).
   PubMed Web of Science ®Google Scholar
• Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am. J. Hematol.74(1), 26–31 (2003).
   PubMed Web of Science ®Google Scholar
• Bernasconi P, Boni M, Cavigliano PM et al. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Leukemia16(10), 2078–2083 (2002).
   PubMed Web of Science ®Google Scholar
• Merlat A, Lai JL, Sterkers Y et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia13(2), 250–257 (1999).
   PubMed Web of Science ®Google Scholar
• Sterkers Y, Preudhomme C, Lai JL et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood91(2), 616–622 (1998).
   PubMed Web of Science ®Google Scholar
• Marusyk A, Wheeler LJ, Mathews CK et al. p53 mediates senescence-like arrest induced by chronic replicational stress. Mol. Cell Biol.27(15), 5336–5351 (2007).
   PubMedGoogle Scholar
• Gottifredi V, Shieh S, Taya Y et al. p53 accumulates but is functionally impaired when DNA synthesis is blocked. Proc. Natl Acad. Sci. USA98(3), 1036–1041 (2001).
   PubMed Web of Science ®Google Scholar
• Marusyk A, DeGregori J. Replicational stress selects for p53 mutation. Cell Cycle6(17), 2148–2151 (2007).
   PubMed Web of Science ®Google Scholar
• Lundin C, Erixon K, Arnaudeau C et al. Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells. Mol. Cell Biol.22(16), 5869–5878 (2002).
   PubMedGoogle Scholar
• Saintigny Y, Delacote F, Vares G et al. Characterization of homologous recombination induced by replication inhibition in mammalian cells. EMBO J.20(14), 3861–3870 (2001).
   PubMed Web of Science ®Google Scholar
• Bertrand P, Saintigny Y, Lopez BS. p53’s double life: transactivation-independent repression of homologous recombination. Trends Genet.20(6), 235–243 (2004).
   PubMedGoogle Scholar
• Bilousova G, Marusyk A, Porter CC et al. Impaired DNA replication within progenitor cell pools promotes leukemogenesis. PLoS Biol.3(12), e401 (2005).
   PubMedGoogle Scholar
• Cramer K, Nieborowska-Skorska M, Koptyra M et al. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res.68(17), 6884–6888 (2008).
   PubMed Web of Science ®Google Scholar
• Plo I, Nakatake M, Malivert L et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood112(4), 1402–1412 (2008).
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Rain JD, Bernard JF et al. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin. Thromb. Hemost.32(4 Pt 2), 417–421 (2006).
   PubMed Web of Science ®Google Scholar
• Gangat N, Wolanskyj AP, McClure RF et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia21(2), 270–276 (2007).
   PubMed Web of Science ®Google Scholar
• Theocharides A, Boissinot M, Girodon F et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood110(1), 375–379 (2007).
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Baxter EJ, Beer PA et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood108(10), 3548–3555 (2006).
   PubMed Web of Science ®Google Scholar
• Spivak JL. An inconvenient truth. Blood115(14), 2727–2728 (2010).
   PubMed Web of Science ®Google Scholar
• Hanft VN, Fruchtman SR, Pickens CV et al. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood95(11), 3589–3593 (2000).
   PubMed Web of Science ®Google Scholar
• Evenson DP, Jost LK. Hydroxyurea exposure alters mouse testicular kinetics and sperm chromatin structure. Cell Prolif.26(2), 147–159 (1993).
   PubMed Web of Science ®Google Scholar
• Ficsor G, Ginsberg LC. The effect of hydroxyurea and mitomycin C on sperm motility in mice. Mutat. Res.70(3), 383–387 (1980).
   PubMed Web of Science ®Google Scholar
• Chapman RM. Effect of cytotoxic therapy on sexuality and gonadal function. Semin. Oncol.9(1), 84–94 (1982).
   PubMed Web of Science ®Google Scholar
• Berthaut I, Guignedoux G, Kirsch-Noir F et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica93, 988–993 (2008).
   PubMed Web of Science ®Google Scholar
• Ferm V. Severe developmental malformations: malformations induced by urethane and hydroxyurea in the hamster. Arch. Pathol.81, 174–177 (1966).
   Google Scholar
• Wilson JG, Scott WJ, Ritter EJ et al. Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys. Teratology11(2), 169–178 (1975).
   PubMedGoogle Scholar
• Cinkotai KI, Wood P, Donnai P et al. Pregnancy after treatment with hydroxyurea in a patient with primary thrombocythaemia and a history of recurrent abortion. J. Clin. Pathol.47(8), 769–770 (1994).
   PubMedGoogle Scholar
• Delmer A, Rio B, Bauduer F et al. Pregnancy during myelosuppressive treatment for chronic myelogenous leukemia. Br. J. Haematol.82(4), 783–784 (1992).
   PubMed Web of Science ®Google Scholar
• Doney KC, Kraemer KG, Shepard TH. Combination chemotherapy for acute myelocytic leukemia during pregnancy: three case reports. Cancer Treat. Rep.63(3), 369–371 (1979).
   PubMedGoogle Scholar
• Sylvester RK, Lobell M, Teresi ME et al. Excretion of hydroxyurea into milk. Cancer60(9), 2177–2178 (1987).
   PubMedGoogle Scholar
• Kennedy BJ, Smith LR, Goltz RW. Skin changes secondary to hydroxyurea therapy. Arch. Dermatol.111(2), 183–187 (1975).
   PubMed Web of Science ®Google Scholar
• Tatarski I, Sharon R. Management of polycythemia vera with hydroxyurea. Semin. Hematol.34(10), 24–28 (1997).
   PubMedGoogle Scholar
• Finazzi G, Caruso V, Marchioli R et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood105(7), 2664–2670 (2005).
   PubMed Web of Science ®Google Scholar
• Abdulkarim K, Girodon F, Johansson P et al. AML transformation in 56 patients with Ph-MPD in two well defined populations. Eur. J. Haematol.82(2), 106–111 (2009).
   PubMed Web of Science ®Google Scholar
• Passamonti F, Malabarba L, Orlandi E et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica88(1), 13–18 (2003).
   PubMed Web of Science ®Google Scholar
• Radaelli F, Onida F, Rossi FG et al. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution. Hematology13(4), 195–202 (2008).
   PubMed Web of Science ®Google Scholar